| Trial ID: | L0506 |
| Source ID: | IRCT20161023030445N2
|
| Associated Drug: |
Propolis
|
| Title: |
Effect of Propolis on liver functional indexes in patients with Non-alcoholic fatty liver disease
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Nonalcoholic fatty liver disease (NAFLD). <br>Fatty (change of) liver, not elsewhere classified
|
| Interventions: |
Intervention 1: Control group: placebo containing starch, oral capsule, 500 mg, twice a day for three months with standard treatment. Intervention 2: Intervention group: Propolis, oral capsule, 500 mg, twice a day for three months with standard treatment.
|
| Outcome Measures: |
Alanine Aminotransferase (ALT). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Aspartate Aminotransferase (AST). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Grade of fatty liver. Timepoint: in the beginning and end of Intervention. Method of measurement: Sonography.;Alkaline Phosphatase (ALP). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Body Mass Index (BMI). Timepoint: in the beginning and end of Intervention. Method of measurement: kg/m2 by measuring height and weight and use of scale.;Gamma glutamyl transpeptidase. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Albumin. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Ferritin. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Bilirubin. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Cholestrol. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Triglyceride. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;High Density Lipoprotein (HDL). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Low Density Lipoprotein (LDL). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.Fasting Blood Serum. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;TNFa. Timepoint: in the beginning and end of Intervention. Method of measurement: Pg/ml by using specific serum kit.;Interleukin 6. Timepoint: in the beginning and end of Intervention. Method of measurement: Pg/ml by using specific serum kit.
|
| Sponsor/Collaborators: |
Vice Chancellor for research of Kurdistan University of Medical Sciences
|
| Gender: |
All
|
| Age: |
20 yearsno limit
|
| Phases: |
Phase 3
|
| Enrollment: |
50
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: using block randomization method with a block size of 4. The list of randomization was computer-generated and a person
|
| Start Date: |
26/03/2018
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
30 April 2018
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/24184
|
